Curative by Design™

Verik Designs For Curative Potential From
Target to Therapy

  • Next, SeleCTR algorithms identify HP Neoantigens within the HCP Protein. more

    High Probability (HP) neoantigens are the unique amino acid sequences (peptides) within an HCP target protein that have a high likelihood of immune (HLA) presentation on the tumor cell surface and recognition by killer T cells.

  • This creates a Toolbox of HP neoantigens. more

    Sets of HCP neoantigens for each target protein become efficient peptide tools for the isolation of the surface molecules used by
    T cells to recognize the neoantigens.

  • The peptide tools are used to produce a panel of HCP T cell receptors (TCRs) that will bind to HP neoantigens on cells expressing the HCP Protein.

  • The TCR genetic machinery is then packaged into a viral vector that can insert the TCR genes into a patient’s T cells.

  • Vector transduction causes a patient’s T cells to

    express the TCR and become potent, cancer- eliminating HCP T cells. more

    ±±The HCP therapy can include T cells to a second neoantigen and/or the co-engineering of an immune modulator such as IL-12 to enhance HCP T cell response.

  • HCP T cells are then transferred to the patient. more

     

    The deliberate, cancer-specific targeting of a HCP T Cell Therapy has the ability to permanently eliminate the solid tumor with minimized off-target damage to normal tissue.

  • Because the HCP Protein is fundamental to a tumor’s ability to persist, its expression continues even as cancer advances. Thus, HCP T cells can eliminate the primary tumor and its metastases at their root even though tumors may change in other ways.

 

© 2017 Verik Bio, Inc
website design by Alice Sargent